Point of care CYP2C19 genotyping after percutaneous coronary intervention-Reference-Cited by-同舟云学术

Point of care CYP2C19 genotyping after percutaneous coronary intervention

Published:2022-04-21 Issue:5-6 Volume:22 Page:303-307
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Baudhuin Linnea M.^ORCID,Train Laura J.,Goodman Shaun G.^ORCID,Lane Gary E.,Lennon Ryan J.,Mathew Verghese,Murthy Vishakantha,Nazif Tamim M.,So Derek Y. F.,Sweeney John P.,Wu Alan H. B.,Rihal Charanjit S.,Farkouh Michael E.,Pereira Naveen L.

Funder

Foundation for the National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.nature.com/articles/s41397-022-00278-4.pdf

Reference21 articles.

1. Gandhi S, Zile B, Tan MK, Saranu J, Bucci C, Yan AT, et al. Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. Can J Cardiol. 2014;30:1725–31.

2. Karve AM, Seth M, Sharma M, LaLonde T, Dixon S, Wohns D, et al. Contemporary use of Ticagrelor in interventional practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Am J Cardiol. 2015;115:1502–6.

3. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306:2704–14.

4. Gaedigk A, Whirl-Carrillo M, Pratt VM, Miller NA, Klein TE. PharmVar and the landscape of pharmacogenetic resources. Clin Pharm Ther. 2020;107:43–6.

5. Botton MR, Whirl-Carrillo M, Del Tredici AL, Sangkuhl K, Cavallari LH, Agundez JAG, et al. PharmVar GeneFocus: CYP2C19. Clin Pharm Ther. 2021;109:352–66.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accuracy and technical characteristics of CYP2C19 point of care tests: a systematic review;Pharmacogenomics;2024-09-04

2. CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association;Circulation;2024-08-06

3. Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors;Genes;2023-02-25

4. Relevance of Pharmacogenomics to the Safe Use of Antimicrobials;Antibiotics;2023-02-21